Evidence map›Paper›PMID 28415775›Full record

ArticleOncotarget2017

Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.

Darko Castven, Michael Fischer, Diana Becker, Stefan Heinrich, Jesper B Andersen, Dennis Strand, Martin F Sprinzl, Susanne Strand, Carolin Czauderna, Stefanie Heilmann-Heimbach and 8 more

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Darko CastvenDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Michael FischerDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Diana BeckerDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Stefan HeinrichDepartment of Surgery, Johannes Gutenberg University, Mainz, Germany.
Jesper B AndersenDepartment of Health and Medical Science, Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Dennis StrandDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Martin F SprinzlDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Susanne StrandDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Carolin CzaudernaDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Stefanie Heilmann-HeimbachDepartment of Genomics, Institute of Human Genetics, Life & Brain Center, University of Bonn, Bonn, Germany.
Stephanie RoesslerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Arndt WeinmannDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Marcus A WörnsDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Snorri S ThorgeirssonLaboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Peter R GalleDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.
Matthias S MatterDepartment of Pathology, University of Basel, Basel, Switzerland.
Hauke LangDepartment of Surgery, Johannes Gutenberg University, Mainz, Germany.
Jens U MarquardtDepartment of Medicine, Johannes Gutenberg University, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular Carcinoma (HCC) commonly develops in chronically damaged liver tissues. The resulting regenerative and inflammatory processes create an adverse milieu that promotes tumor-initiation and progression. A better understanding of the hepatic tumor-microenvironment interaction might infer profound therapeutic implications.Integrative whole genome and transcriptome analyses of different tumor regions, the invasive tumor border and tumor-surrounding liver (SL) were performed to identify associated molecular alterations and integrated with our existing HCC database. Expression levels and localization of established CSC markers were assessed in pre-neoplastic lesions and confirmed in two independent patient cohorts using qRT-PCR, immunohistochemistry and immunofluorescence.Our results indicate that genomic and transcriptomic profiles between SL and different tumor regions are quite distinct. Progressive increase in genetic alterations and activation of pathways related to proliferation as well as apoptosis were observed in the tumor tissue, while activation of stemness markers was present in cirrhotic SL and continuously decreased from pre-neoplastic lesions to HCC. Interestingly, the invasive tumor border was characterized by inflammatory and EMT-related gene sets as well as activation of pro-survival signaling. Consistently, integration of gene expression signatures with two independent HCC databases containing 300 HCCs revealed that border signatures are predictive of HCC patient survival.Prognostic significance of the permissive liver microenvironment might be a consequence of a pro-oncogenic field effect that is caused by chronic regenerative processes. Activation of key oncogenic features and immune-response signaling indicates that the cross-talk between tumor and microenvironment might be a promising therapeutic and/or preventive target.

Indexed as

Genetic VariationCarcinoma, HepatocellularCell Line, TumorCell ProliferationGene Expression ProfilingGenomicsHumansImmunohistochemistryLiver NeoplasmsMicroscopy, ConfocalNeoplastic Stem CellsTranscriptomeTumor Microenvironmentfield effecthepatocarcinogenesisliver cancermicroenvironmentstemness features

Identifiers

PMID28415775
PMCPMC5564717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.